³í¹®) Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
¿¬¼¼¾Ïº´¿ø Æó¾Ï¼¾ÅÍ Á¶º´Ã¶ ¼¾ÅÍÀå(»çÁø Á¾¾ç³»°ú)